share_log

Roth MKM Maintains Buy on Champions Oncology, Lowers Price Target to $7.5

Roth MKM Maintains Buy on Champions Oncology, Lowers Price Target to $7.5

Roth MKM维持对Champions Oncology的买入,将目标价下调至7.5美元
Benzinga ·  2023/09/22 23:40

Roth MKM analyst Scott Henry maintains Champions Oncology (NASDAQ:CSBR) with a Buy and lowers the price target from $9 to $7.5.

Roth MKM分析师Scott Henry维持冠军肿瘤学(纳斯达克:CSBR)的Buy,并将目标价从9美元下调至7.5美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发